COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: Effects on the negative symptom response to clozapine

Pharmacogenomics

Volumn 16, Issue 1, 2015, Pages 35-44

  Bosia, Marta ^a,b   Lorenzi, Cristina ^a   Pirovano, Adele ^c   Guglielmino, Carmelo ^a   Cocchi, Federica ^a   Spangaro, Marco ^a,c   Bramanti, Placido ^d   Smeraldi, Enrico ^a,c   Cavallaro, Roberto ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b SCUOLA UNIVERSITARIA SUPERIORE IUSS PAVIA   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

clozapine; genetic polymorphisms; negative symptoms; PANSS; Positive and Negative Symptoms Scale; psychopharmacogenetics; psychosis; schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; CLOZAPINE; GENOMIC DNA; METHIONINE; NEUROLEPTIC AGENT; SEROTONIN 1A RECEPTOR; VALINE; COMT PROTEIN, HUMAN; DOPAMINE; PHARMACOLOGICAL BIOMARKER;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DOPAMINERGIC SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DSM-IV; FEMALE; GENETIC POLYMORPHISM; HUMAN; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; NEUROMODULATION; PHARMACOGENETICS; PHENOTYPIC VARIATION; POLYMERASE CHAIN REACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PREFRONTAL CORTEX; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA; SEQUENCE ANALYSIS; SEROTONINERGIC SYSTEM; TREATMENT RESPONSE; VENOUS BLOOD; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BIOMARKERS, PHARMACOLOGICAL; CATECHOL O-METHYLTRANSFERASE; CLOZAPINE; DOPAMINE; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT1A; SCHIZOPHRENIA;

EID: 84920854903     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.150     Document Type: Article

References (58)

1. Grunder G, Hippius H, Carlsson A. The ?atypicality' of antipsychotics: a concept re-examined and re-defined. Nat. Rev. Drug Discov. 8(3), 197-202 (2009
2. Raja M, Raja S. Clozapine safety years later. Curr. Drug Saf. 9(3), 163-195 (2014
3. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 158(4), 518-526 (2001
4. Miller R. Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I. Curr. Neuropharmacol. 7(4), 302-314 (2009
5. Diaz-Mataix L, Artigas F, Celada P. Activation of pyramidal cells in rat medial prefrontal cortex projecting to ventral tegmental area by a 5-HT1A receptor agonist. Eur. Neuropsychopharmacol. 16(4), 288-296 (2006
6. Ettinger U, Williams Sc, Fannon D et al. Functional magnetic resonance imaging of a parametric working memory task in schizophrenia: relationship with performance and effects of antipsychotic treatment. Psychopharmacology (Berl.) 216(1), 17-27 (2011
7. Purkayastha S, Ford J, Kanjilal B et al. Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II-NMDA receptor interactions. J. Neurochem. 120(3), 396-407 (2012
8. Lotta T, Vidgren J, Tilgmann C et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34(13), 4202-4210 (1995
9. Winterer G, Weinberger DR. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 27(11), 683-690 (2004
10. Eisenberg DP, Sarpal D, Kohn PD et al. Catechol-O-methyltransferase valine(158)methionine genotype and resting regional cerebral blood flow in medication-free patients with schizophrenia. Biol. Psychiatry 67(3), 287-290 (2010
11. Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am. J. Psychiatry 159(4), 652-654 (2002
12. Kang WS, Park JK, Park HJ et al. Association between catechol-O-methyltransferase Val158Met polymorphism and negative symptoms of schizophrenia in the Korean population. Psychiatry Res. 198(2), 338-339 (2012
13. Pelayo-Teran JM, Crespo-Facorro B, Carrasco-Marin E et al. Catechol-O-methyltransferase Val158Met polymorphism and clinical characteristics in first episode non-affective psychosis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(5), 550-556 (2008
14. Tsai SJ, Hong CJ, Yu YW, Chen TJ. Association study of catechol-O-methyltransferase gene and dopamine D4 receptor gene polymorphisms and personality traits in healthy young chinese females. Neuropsychobiology 50(2), 153-156 (2004
15. Wang Y, Fang Y, Shen Y, Xu Q. Analysis of association between the catechol-O-methyltransferase (COMT) gene and negative symptoms in chronic schizophrenia. Psychiatry Res. 179(2), 147-150 (2010
16. Molero P, Ortuno F, Zalacain M, Patino-Garcia A. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J. 7(6), 418-426 (2007
17. Anttila S, Illi A, Kampman O, Mattila KM, Lehtimaki T, Leinonen E. Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics 14(5), 303-307 (2004
18. Inada T, Nakamura A, Iijima Y. Relationship between catechol-O-methyltransferase polymorphism and treatment-resistant schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 120B(1), 35-39 (2003
19. Illi A, Kampman O, Hanninen K et al. Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia. Hum. Psychopharmacol. 22(4), 211-215 (2007
20. Pelayo-Teran JM, Perez-Iglesias R, Vazquez-Bourgon J et al. Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis. Psychiatry Res. 185(1-2), 286-289 (2011
21. Bertolino A, Caforio G, Blasi G et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry 161(10), 1798-1805 (2004
22. Bosia M, Bechi M, Marino E et al. Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia. Neurosci. Lett. 417(3), 271-274 (2007
23. Weickert TW, Goldberg TE, Mishara A et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol. Psychiatry 56(9), 677-682 (2004
24. Heusler P, Bruins Slot L, Tourette A, Tardif S, Cussac D. The clozapine metabolite N-desmethylclozapine displays variable activity in diverse functional assays at human dopamine D(2) and serotonin 5-HT(1)A receptors. Eur. J. Pharmacol. 669(1-3), 51-58 (2011
25. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol. Psychiatry 48(3), 229-237 (2000
26. Kobilka BK, Frielle T, Collins S et al. An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. Nature 329(6134), 75-79 (1987
27. Meneses A. 5-HT system and cognition. Neurosci. Biobehav. Rev. 23(8), 1111-1125 (1999
28. Steckler T, Sahgal A. Psychopharmacological studies in rats responding at touch-sensitive devices. Psychopharmacology (Berl.) 118(2), 226-229 (1995
29. Lemonde S, Turecki G, Bakish D et al. Impaired trans-repression at a 5-HT1A receptor gene polimorphism associated with major depression and suicide. J. Neurosci. 23(25), 8788-8799 (2003
30. Albert PR. Transcriptional regulation of the 5-HT1A receptor: implications for mental illness. Philos. Trans. R Soc. Lond. B Biol. Sci. 367(1601), 2402-2415 (2012
31. Angles MR, Ocana DB, Medellin BC, Tovilla-Zarate C. No association between the HTR1A gene and suicidal behavior: a meta-analysis. Rev. Bras. Psiquiatr. 34(1), 38-42 (2012
32. Gonzalez-Castro TB, Tovilla-Zarate CA, Juarez-Rojop I et al. Association of 5HTR1A gene variants with suicidal behavior: case-control study and updated meta-analysis. J. Psychiatr. Res. 47(11), 1665-1672 (2013
33. Drago A, Ronchi DD, Serretti A. 5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Int. J. Neuropsychopharmacol. 11(5), 701-721 (2008
34. Gross C, Zhuang X, Stark K et al. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416(6879), 396-400 (2002
35. Lemonde S, Du L, Bakish D, Hrdina P, Albert PR. Association of the C(1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Psychopharmacology (Berl.) 24, 24 (2004
36. Strobel A, Gutknecht L, Rothe C et al. Allelic variation in 5-HT1A receptor expression is associated with anxiety-and depression-related personality traits. J. Neural Transm. 110(12), 1445-1453 (2003
37. Kato M, Fukuda T, Wakeno M et al. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B(1), 115-123 (2009
38. Kim YK, Yoon HK. Effect of serotonin-related gene polymorphisms on pathogenesis and treatment response in Korean schizophrenic patients. Behav. Genet. 41(5), 709-715 (2011
39. Mossner R, Schuhmacher A, Kuhn KU et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet. Genomics 19(1), 91-94 (2009
40. Wang L, Fang C, Zhang A et al. The ?1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J. Psychopharmacol. 22(8), 904-909 (2008
41. Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am. J. Psychiatry 163(10), 1826-1829 (2006
42. Bosia M, Bechi M, Pirovano A et al. COMT and 5-HT1A-receptor genotypes potentially affect executive functions improvement after cognitive remediation in schizophrenia. Health Psychol. Behav. Med. 2(1), 509-516 (2014
43. Tang H, Dalton CF, Srisawat U, Zhang ZJ, Reynolds GP. Methylation at a transcription factor-binding site on the 5-HT1A receptor gene correlates with negative symptom treatment response in first episode schizophrenia. Int. J. Neuropsychopharmacol.17(4), 645-649 (2013
44. Cavallaro R, Brambilla P, Smeraldi E. The sequential treatment approach to resistant schizophrenia with risperidone and clozapine: results of an open study with follow-up. Hum. Psychopharmacol. Clin. Exp. 13(2), 91-97 (1998
45. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13(2), 261-276 (1987
46. Wykes T, Reeder C, Corner J, Williams C, Everitt B. The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophr. Bull. 25(2), 291-307 (1999
47. Bosia M, Anselmetti S, Bechi M et al. Effect of 5-HT1A-receptor functional polymorphism on Theory of Mind performances in schizophrenia. Psychiatry Res. 188(2), 187-190 (2011
48. Strous RD, Lapidus R, Viglin D, Kotler M, Lachman HM. Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia. Neurosci. Lett. 393(2-3), 170-173 (2006
49. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT. Data quality control in genetic case-control association studies. Nat. Protoc. 5(9), 1564-1573 (2010
50. Lindenmayer JP, Czobor P, Volavka J et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J. Clin. Psychiatry 65(4), 551-556 (2004
51. Wang CS, Yang YK, Chen M, Chiu NT, Yeh TL, Lee IH. Negative symptoms and regional cerebral blood flow in patients with schizophrenia: a single photon emission computed tomography study. Kaohsiung J. Med. Sci. 19(9), 464-469 (2003
52. O'Leary DS, Flaum M, Kesler ML, Flashman LA, Arndt S, Andreasen NC. Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J. Neuropsychiatry Clin. Neurosci. 12(1), 4-15 (2000
53. Tauscher J, Hussain T, Agid O et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am. J. Psychiatry 161(9), 1620-1625 (2004
54. Slifstein M, Kolachana B, Simpson EH et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol. Psychiatry 13(8), 821-827 (2008
55. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J. Pharmacol. Exp. Ther. 295(3), 853-861 (2000
56. Perry KW, Hemrick-Leucke S, Evans DC et al. Do atypical antipsychotic agents interact with 5-HT1A receptors and monoamine uptake sites in vivo. Am. Soc. Neurosci. Abstr. 24, 772 (1998
57. Umbricht DS, Wirshing WS, Wirshing DA et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J. Clin. Psychiatry 63(5), 420-424 (2002
58. Nielsen J, Nielsen RE, Correll CU et al. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J. Clin. Psychopharmacol. 32(5), 678-683 (2012).